Clinical Trial Update: Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients [Phase 2]

View source ↗

Summary

Phase 2 trial of plerixafor (AMD3100) in patients with Non-Hodgkin lymphoma and multiple myeloma has completed with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Plerixafor (Plerixafor)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2010-11-25